The Many Mutations of the COVID-19 Variant: Current Perspectives on EG.5/Eris

Viral diseases pose a significant threat to public health around the world. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was originally identified in Wuhan, China, in 2019. Throughout the epidemic, SARS-CoV-2 has continually changed genetically, giving rise to variants that are disti...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखक: Abayeneh Girma (लेखक)
स्वरूप: पुस्तक
प्रकाशित: SAGE Publishing, 2023-12-01T00:00:00Z.
विषय:
ऑनलाइन पहुंच:Connect to this object online.
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9f46a3fc4d6b4412a4f43c223cf67e93
042 |a dc 
100 1 0 |a Abayeneh Girma  |e author 
245 0 0 |a The Many Mutations of the COVID-19 Variant: Current Perspectives on EG.5/Eris 
260 |b SAGE Publishing,   |c 2023-12-01T00:00:00Z. 
500 |a 1178-6302 
500 |a 10.1177/11786302231217805 
520 |a Viral diseases pose a significant threat to public health around the world. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was originally identified in Wuhan, China, in 2019. Throughout the epidemic, SARS-CoV-2 has continually changed genetically, giving rise to variants that are distinct from the original virus. SARS-CoV-2 has a high-frequency mutation rate, resulting in more genetic diversity. EG.5/Eris is a subvariant and descendant of Omicron, which remains the world's most prevalent coronavirus strain of current concern. The percentage of EG.5 recorded has steadily increased across the board. Epidemiological week 29 (17-23 July 2023) saw a 17.4% global prevalence of EG.5. Mutations in the virus's genome can cause false-negative results in molecular detection and cause increased transmissibility, morbidity, and mortality due to a reduction in vaccine efficiency. Furthermore, these changes in S-protein structure alter the neutralising ability of neutralising antibodies (Nabs), resulting in a reduction in vaccine efficiency. Therefore, all countries should take efficient infection prevention and control measures as per the guidelines of the world, continental, and their country's health organisations, along with vaccine and treatment investigations. 
546 |a EN 
690 |a Environmental sciences 
690 |a GE1-350 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Environmental Health Insights, Vol 17 (2023) 
787 0 |n https://doi.org/10.1177/11786302231217805 
787 0 |n https://doaj.org/toc/1178-6302 
856 4 1 |u https://doaj.org/article/9f46a3fc4d6b4412a4f43c223cf67e93  |z Connect to this object online.